This information collection request collects information from an adult sample of individuals who self-identify as having rheumatoid arthritis or overactive bladder regarding their perceptions of the important safety information and brief summary in direct-to-consumer prescription drug print advertising. Additionally, we will collect eye-tracking data to observe participants’ gaze maps while reading the information. Using an in-person interview methodology, we plan to conduct two 60-minute pilots with a total of 40 adults and two 60-minute studies with a total of 400 adults.
The latest form for Experimental Study of Risk Information Amount and Location in Direct-to-Consumer Print Ads expires 2020-09-30 and can be found here.
Document Name |
---|
Justification for No Material/Nonsubstantive Change |
Supporting Statement B |
Supporting Statement A |
Approved with change |
No material or nonsubstantive change to a currently approved collection | 2019-07-24 | |
Approved with change |
New collection (Request for a new OMB Control Number) | 2018-08-15 |
Federal Enterprise Architecture: Health - Consumer Health and Safety